Doris Hinterberger
YOU?
Author Swipe
View article: Prothrombin complex concentrate in managing direct oral anticoagulant (DOAC)-associated bleeding and real-world use in vitamin k antagonist (VKA)-associated bleeding: The ongoing lex-210 and lex-212 studies
Prothrombin complex concentrate in managing direct oral anticoagulant (DOAC)-associated bleeding and real-world use in vitamin k antagonist (VKA)-associated bleeding: The ongoing lex-210 and lex-212 studies Open
Background and Significance: Four-factor prothrombin complex concentrates (4F-PCCs) are approved for rapid reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy in adult patients presenting with m…
View article: Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates
Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates Open
Importance Millions of people take vitamin K antagonists (VKAs). Some people who need urgent surgical procedures require rapid VKA reversal to prevent excessive intraoperative bleeding. Objective To evaluate the hemostatic noninferiority o…
View article: Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study Open
EudraCT 2015-005443-14, NCT02638207.
View article: Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy
Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy Open
Intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy usually starts with a 2.0 g/kg induction dose followed by 1.0 g/kg maintenance doses every 3 weeks. No dose-ranging studies with intravenous immunog…